Ziad Bakouny

Ziad Bakouny

Auto-generated profile, based on publicly available information

Ziad Bakouny

Memorial Sloan Kettering Cancer Center, New York, NY

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 May 2020 in Nature Medicine
Verified
Journal Article
Closed access
PDF file
DBDavid A. Braun
David A. Braun
YHYue Hou
Yue Hou
ZBZiad Bakouny
Ziad Bakouny
MFMiriam Ficial
Miriam Ficial
MAMiriam Sant’ Angelo
Miriam Sant’ Angelo
TCToni K. Choueiri
Toni K. Choueiri

1 May 2021 in Cancer Cell
Verified
Journal Article
Open access
KBKevin Bi
Kevin Bi
MHMeng Xiao He
Meng Xiao He
ZBZiad Bakouny
Ziad Bakouny
AKAbhay Kanodia
Abhay Kanodia
SNSara Napolitano
Sara Napolitano
EAEliezer Van Allen
Eliezer Van Allen
Immune checkpoint blockade (ICB) results in durable disease control in a subset of patients with advanced renal cell carcinoma (RCC), but mechanisms driving resistance are poorly understood. We characterize the single-cell transcriptomes of cancer and immune cells from metastatic RCC patients before or after ICB exposure. In responders, subsets of cytotoxic T cells express higher levels of co-inhibitory receptors and effector molecules. Macrophages from treated biopsies shift toward pro-inflammatory states in response to an interferon-rich microenvironment but also upregulate immunosuppressive markers. In cancer cells, we identify bifurcation into two subpopulations differing in angiogenic signaling and upregulation of immunosuppressive programs after ICB. Expression signatures for cancer cell subpopulations and immune evasion are associated with PBRM1 mutation and survival in primary and ICB-treated advanced RCC. Our findings demonstrate that ICB remodels the RCC microenvironment and modifies the interplay between cancer and immune cell populations critical for understanding response and resistance to ICB.

1 May 2021 in Cancer Cell
Verified
Journal Article
Closed access
DBDavid A. Braun
David A. Braun
KSKelly Street
Kelly Street
KBKelly P. Burke
Kelly P. Burke
DCDavid L. Cookmeyer
David L. Cookmeyer
TDThomas Denize
Thomas Denize
CWCatherine J. Wu
Catherine J. Wu

22 June 2020 in Nature Medicine
Verified
Journal Article
Open access
PDF file
NVNuzzo Pier Vitale
Nuzzo Pier Vitale
JBJacob E. Berchuck
Jacob E. Berchuck
KKKeegan Korthauer
Keegan Korthauer
SSSandor Spisak
Sandor Spisak
Amin NassarAmin Nassar
Amin Nassar
MFMatthew Freedman
Matthew Freedman
Improving early cancer detection has the potential to substantially reduce cancer-related mortality. Cell-free methylated DNA immunoprecipitation and high-throughput sequencing (cfMeDIP–seq) is a highly sensitive assay capable of detecting early-stage tumors. We report accurate classification of patients across all stages of renal cell carcinoma (RCC) in plasma (area under the receiver operating characteristic (AUROC) curve of 0.99) and demonstrate the validity of this assay to identify patients with RCC using urine cell-free DNA (cfDNA; AUROC of 0.86).

1 November 2020 in Cancer Cell
Verified
Journal Article
Closed access
ZBZiad Bakouny
Ziad Bakouny
JHJessica E. Hawley
Jessica E. Hawley
TCToni K. Choueiri
Toni K. Choueiri
SPSolange Peters
Solange Peters
BRBrian I. Rini
Brian I. Rini
CPCorrie A. Painter
Corrie A. Painter

4 March 2021 in Nature Medicine
Verified
Journal Article
Open access
PDF file
MHMeng Xiao He
Meng Xiao He
MCMichael S. Cuoco
Michael S. Cuoco
JCJett Crowdis
Jett Crowdis
ABAlice Bosma-Moody
Alice Bosma-Moody
ZZZhenwei Zhang
Zhenwei Zhang
EAEliezer Van Allen
Eliezer Van Allen
Metastatic castration-resistant prostate cancer is typically lethal, exhibiting intrinsic or acquired resistance to second-generation androgen-targeting therapies and minimal response to immune checkpoint inhibitors1. Cellular programs driving resistance in both cancer and immune cells remain poorly understood. We present single-cell transcriptomes from 14 patients with advanced prostate cancer, spanning all common metastatic sites. Irrespective of treatment exposure, adenocarcinoma cells pervasively coexpressed multiple androgen receptor isoforms, including truncated isoforms hypothesized to mediate resistance to androgen-targeting therapies2,3. Resistance to enzalutamide was associated with cancer cell–intrinsic epithelial–mesenchymal transition and transforming growth factor-β signaling. Small cell carcinoma cells exhibited divergent expression programs driven by transcriptional regulators promoting lineage plasticity and HOXB5, HOXB6 and NR1D2 (refs.4–6). Additionally, a subset of patients had high expression of dysfunction markers on cytotoxic CD8+T cells undergoing clonal expansion following enzalutamide treatment. Collectively, the transcriptional characterization of cancer and immune cells from human metastatic castration-resistant prostate cancer provides a basis for the development of therapeutic approaches complementing androgen signaling inhibition.